Atorvastatin Lowers Plasma Matrix Metalloproteinase-9 in Patients with Acute Coronary Syndrome
Open Access
- 1 April 2004
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 50 (4), 750-753
- https://doi.org/10.1373/clinchem.2003.026070
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Statins Reduce Inflammation in Atheroma of Nonhuman Primates Independent of Effects on Serum CholesterolArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Inflammation and AtherosclerosisCirculation, 2002
- Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled TrialJAMA, 2001
- Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid PlaquesCirculation, 2001
- An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In VitroCirculation, 2001
- Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromesJournal of the American College of Cardiology, 1998
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Coronary Plaque DisruptionCirculation, 1995
- Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.JCI Insight, 1994
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992